# Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

> **NCT02227368** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Peripheral Artery Disease (PAD)

## Interventions

- **DRUG:** Ticagrelor
- **DRUG:** Comparator

## Key facts

- **NCT ID:** NCT02227368
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-20
- **Primary completion:** 2016-05-23
- **Final completion:** 2016-05-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227368, "Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02227368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*